The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Putilina M.V.

Kafedra nevrologii fakulteta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Endothelium as a target for new therapeutic strategies in cerebral vascular diseases

Authors:

Putilina M.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(10): 122‑130

DOI: 10.17116/jnevro2017117101122-130

Views: 4797

Downloaded: 109

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Putilina MV. Endothelium as a target for new therapeutic strategies in cerebral vascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(10):122‑130. (In Russ.)
https://doi.org/10.17116/jnevro2017117101122-130

 
МСФ на ЯМ
Close metadata
Recommended articles:
Treatment of patients with ishe­mic stroke in the vertebral-basilar system in acute period: expe­rience of using the neuroprotective drug Mexi­dol. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):78-84
Cere­bral hemo­dynamic diso­rders in patients with schi­zophrenia with concomitant meta­bolic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):80-85
A role of cere­brovascular diseases in the progression of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):53-57
Inte­grative asse­ssment of the effe­ctiveness and safety of outpatient use of Pica­milon. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):119-130
Place of oligopeptide H-Met-Glu-His-Phe-Pro-Gly-Pro-OH in the therapy and reha­bilitation of patients with ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):56-63
Posterior reve­rsible ence­phalopathy syndrome in autoimmune diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):50-57
Clinical effi­cacy and safety of Pica­milon in patients with progressive chro­nic cere­bral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):71-80
Reco­gnan (citicoline) prescribing in cere­brovascular diseases and type 2 diabetes mellitus patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):23-27
Mortality from cere­brovascular diseases in the Russian Fede­ration before and during the COVID-19 epidemy: regional differences. Russian Journal of Preventive Medi­cine. 2024;(4):12-17
Changes in the lipid profile, stru­ctural and functional states of blood vessels in patients with lymphomas and cardiovascular toxic risks during the chemotherapy. Russian Journal of Preventive Medi­cine. 2024;(10):117-124

The author evaluates a role of endothelium in the pathogenesis of cerebral vascular diseases (CVD) and considers the concept about endothelium as prevention and treatment of pathological processes leading to or triggering CVD. There are two medical strategies for correction of endothelium dysfunction in CVD: tactic (using of antioxidants) and strategic (statins, hypotensive drugs, antiaggregants).

Keywords:

endothelium dysfunction
cerebral vascular diseases
dipyridamole
succinic acid derivatives

Authors:

Putilina M.V.

Kafedra nevrologii fakulteta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

List of references:

  1. Voloshin VP, Malakhov VA, Zavgorodnyaya AN. Endothelial dysfunction in patients with cerebral ischemic stroke: gender, age, severity of the disease, new possibilities of drug correction. Intern neuro journal. 2007;2(12):15-20. (In Russ.)
  2. Voloshin VP, Malakhov VA, Zavgorodnyaya AN. Endothelial dysfunction in cerebrovascular disease. Kharkov; 2006. (In Russ.)
  3. Putilina MV. Correction of endothelial dysfunction in patients with cerebrovascular disease. Handbook for Practitioners Doctors. 2014;10:33-39. (In Russ.)
  4. Fedin AI, Old EP, Putilin MV, Old EV, Mironova OP, Badalyan KR. Endothelial dysfunction in patients with chronic cerebral ischemia and possibilities of its pharmacological correction of the. Attending physician. 2015;5:15-18. (In Russ.)
  5. Gotto AM. the Development of concepts of dyslipidemia, atherosclerosis and cardiovascular diseases. RMJ. 2006;3:14-18. (In Russ.)
  6. Zotova IV, Entertainers DA, Sidorenko BA. the Synthesis of nitric oxide and atherosclerosis. Cardiology. 2002;34:58-67. (In Russ.)
  7. Putilina MV. The Role of arterial hypertension in development of chronic disorders of cerebral circulation. Jour. of neurology and psychiatry. S.S. Korsakov. 2014;114: 9:119-123. (In Russ.)
  8. Michael T, Gewaltig M, Kojda G. Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovascular research. 2002;55:205-260.
  9. Gamboa A, Abraham R, Diedrich A. Role of Adenosine and Nitric Oxide on the Mechanisms of Action of Dipiridamole. Stroke. 2005;36:2170-2175.
  10. Gryglewski ZW. Involvement of free radicals in the transformation of endothelial prostacyclin and nitric oxide. News of medicine and pharmacy. 1997;1(2):2-8. (In Russ.)
  11. Stoclet JC, Muller BR, Andriantsitohaina R, Kleshchev A. Giperprodukcia of nitric oxide in pathophysiology of blood vessels. Biochemistry. 2014;63(7):976-983. (In Russ.)
  12. Wang D, Gill PS, Chabrashvili T, Onozato ML, Raggio J, Mendonca M. Isoform-specific regulation by N(G), N(G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor NO. Circulation Research. 2007;101: 627-635.
  13. Gainutdinov AR. The Role of asymmetric dimethylarginine in patients with coronary heart disease. Abstract of PhD thesis. Kazan; 2012. (In Russ.)
  14. Xuan C, Tian QW, Li H, Zhang BB, He GW, Lun LM. Levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and risk of coronary artery disease: A meta-analysis based on 4713 participants. European Journal of Preventive Cardiology. 2016;23(5):502-510.
  15. Borisov SN, Gendlin GE. The Use of natriuretic peptides in the diagnosis of chronic heart failure. Atmosphere. News of cardiology. 2011;2:13-17. (In Russ.)
  16. Fedotova IN, Belopolsky AA, Sturov NV. The diagnostic significance of NT-proBNP in cardiac patients. Difficult patient. 2013;7:23. (In Russ.)
  17. Thrombomodulin in the damage of endothelial cells in vasculitis. The link is active on: 26.07.2017. Available at: http://medbe.ru/materials/vaskulity-i-vaskulopatii/trombomodulin-v-povrezhdenii-endotelialnykh-kletok-pri-vaskulitakh/medbe.ru (In Russ.)
  18. Shushlebin OI, Kononenko LG, Manik IM. Von Willebrand Factor and its role in endothelial dysfunction in ischemic heart disease: diagnosis, criteria of the forecast and prospective approaches to therapy. (In Russ.)
  19. Bongers TN, de Maat MP, van Goor ML. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke. 2006;37(11):2672-2677.
  20. Kudryasheva OV, Staikov DA, Sidorenko BA. the Endothelial hemostasis: thrombomodulin system and its role in the development of atherosclerosis and its complications. Cardiology. 2000;40(8):65-70. (In Russ.)
  21. Odinak MM, Janiszewski SN, Voznyuk IA. The Level of plasma homocysteine, the risk of cerebrovascular disease and b vitamins. Medline Express. 2008;1:20-23. (In Russ.)
  22. Ford AH, Flicker L, Alfonso H, Hankey GJ, Norman PE, van Bockxmeer FM, Almeida OP. Plasma homocysteine and MTHFRC677T polymorphism as risk factors for incident dementia. J Neurol Neurosurg Psychiatry. 2012;83:70-75. https://doi.org/10.1136/jnnp.2011.242446
  23. Fedin AI, Efimov VS, Kalieva AZ, Kromm MA. Hyperhomocysteinemia as a risk factor of stroke. Journal of neurology and psychiatry im S.S. Korsakova (Annex «a Stroke»). 2002;6:24-28. (In Russ.)
  24. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk forcardiovascular disease: a randomized trial. JAMA. 2008;299:2027-2036. https://doi.org/10.1001/jama.299.17.2027
  25. Jardine MJ, Kang A, Zoungas S, Navaneethan SD, Nino-miya T, Nigwekar SU, Gallagher MP, Cass A, Strippoli G, Perkovic V. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. BMJ (Clinical research ed.). 2012;344:3533. PMC 3374481. PMID: 22695899. https://doi.org/10.1136/bmj.e3533Review
  26. Smach MA, Jacob N, Golmard JL. Folate and homocysteine in the cerebrospinal fluid of patients with Alzheimer’s disease or dementia: a case control study. European Neurology. 2011;65(5):270-278. https://doi.org/10.1159/000326301
  27. Dzyak LA, Zurkalenco ES. Stroke in young patients. Practical angiology. 2010;2:9-14. (In Russ.)
  28. Filimonov DA, Yevtushenko SK, Dyuba DSh, Simonyan VA. Relationship of homocysteine with hemostasis and the possibility of drug correction in patients with cerebrovascular disease and risk factors of its development. Ukrainian Bulletin of Psychoneurology. 2012;20(3):72:147. (In Russ.)
  29. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG, Hinchey JA, Howard VJ, Jauch EC, Levine SR, Meschia JF, Moore WS, Nixon JV, Pearson TA. Guidelines for the primary prevention of stroke. A guideline for bhealthcare professionals from the American Heart Association. American Stroke Association. Stroke. 2011;42(2):517-584. Epub 2010 Dec 2. Erratum in: Stroke. 2011;42(2):26. https://doi.org/10.1161/STR.0b013e3181fcb238
  30. Putilina MV. The Role of endothelial dysfunction in cerebrovascular diseases. Doctor. 2012;7:24-28. (In Russ.)
  31. Zavgorodnyaya AN, Malakhov VA. Endothelial mechanisms of pathogenesis of cerebrovascular disease. Ukr med journal. 2006;2(52):32-39. (In Russ.)
  32. Putilina MV. Combined therapy of cerebrovascular disorders with neuroprotectors. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116:11:57-62. (In Russ.)
  33. Golovchenko YuI, Trishchynska MA. Modern conception of cerebral vessel endothelium physiology and pathology Consilium medicum Ukraina. 2008;11:739-740. (In Russ.)
  34. Zadionchenko VC, Adasheva T V. Endothelial dysfunction and arterial hypertension: therapeutic opportunities. RMJ. 2002;10(1):145:11-15. (In Russ.)
  35. Belenkov YuN, Mareev VY, Ageev FT. The angiotensin-converting enzyme in the treatment of cardiovascular diseases (Quinapril and endothelial dysfunction). M. 2001. (In Russ.)
  36. Chrysant SG. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotesin-converting enzyme inhibitors: clinical and experimental evidence. J of human Hypertension. 2005;19:923-931.
  37. Varakin YuYa. Lipid-lowering therapy in the prevention of ischemic stroke. Atmosphere. Nevr Disease. 2006;3:2-6. (In Russ.)
  38. Malaya LT, Korzh AN, Balkove LB. Endothelial dysfunction in the pathology of the cardiovascular system. Kharkov: Publishing house TORSING; 2000. (In Russ.)
  39. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457-507. https://doi.org/10.1159/000131083
  40. Ambrose JA, Martinez EE. A New Paradigm for Plaque Stabilization. Circulation. 2002;105:2000-2004. https://doi.org/10.1161/01.CIR.0000012528.89469.8E
  41. Vorob’eva OV. Pleiotropic effects dipyridamole: clinical perspectives. Effective pharmacotherapy Nevrology. 2016;3(25):15-18. (In Russ.)
  42. Balakumar P, Nyoa Y, Renushiaa R. Classical and pleiotropic actions of dipyridamole:Not enough light toilluminate the dark tunnel? Pharmacol Res. 2014;87:144-150. https://doi.org/10.1016/j.phrs.2014.05.008
  43. Tanashyan MM, Domashenko M A. Application has chimes in chronic cerebrovascular disease. Atmosphere. Nervous diseases. 2005;3:8-11. (In Russ.)
  44. Aktas B, Utz A, Hoenig-Liedl P. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets:in vitro and in vivo/ex vivo studies. Stroke. 2003;34(3):764-769. https://doi.org/10.1161/01.STR.0000056527.34434.59
  45. Ernens I, LОonard F, Vausort M. Adenosine up-regulates vascular endothelialgrowth factor in human macrophages. Biochem Biophys Res Commun. 2010;392(3):351-356. https://doi.org/10.1016/j.bbrc.2010.01.023
  46. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148(2):209-214. PMID: 10657556.
  47. Verro P, Gorelick P, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke. 2008;39(4)1358-1363. https://doi.org/10.1161/STROKEAHA.107.496281
  48. Barzegar A. Proton-Coupled Electron-Transfer Mechanism for the Radical ScavengingActivity of Cardiovascular Drug Dipyridamole. PLoS ONE. 2012;7(6):39660. https://doi.org/10.1371/journal.pone.0039660):764—9
  49. Massaro M, Scoditti E, Carluccio M. Dipyridamole decreases inflammatory metalloproteinase-9 expressionand release by human monocytes. Thromb Haemost. 2013;109:280-289. https://doi.org/10.1160/TH 12-05-0326
  50. Kareva EN. Features of the pharmacological action and application of dipyridamole in the prevention and treatment of viral infections. Consilium medicum. 2016;18(9):124-131. (In Russ.)
  51. Wang Ch, Schwab LP, Fan M Seagroves T. N., Buolamwini J. K. Chemoprevention Activity of Dipyridamole in the MMTV-PyMT Transgenic Mouse Model of Breast Cancer. Cancer Prev Res (Phila). 2013;6(5). https://doi.org/10.1158/1940-6207.CAPR-12-0345
  52. Ragulina VA. Endotheliopathy and cardioprotective effects of some derivatives of 3-hydroperoxide in the modeling of endotoxin-induced model of endothelial dysfunctions. International journal of applied and fundamental research. 2016;6(1):70-73. (In Russ.)
  53. Putilina MV. Comorbid patient in clinical practice. Consilium medicum. 2017;19(2):64-71. (In Russ.)
  54. Putilina MV. Combined neuroprotective therapy of cerebrovascular diseases. Doctor. 2012;4:69-73. (In Russ.)
  55. Torshin IY, Gromova OA, Sardaryan IS, Fedotova LE, Semenov VA. Comparative analysis hemorheology Mexidol. Pharmacokinetics and Pharmacodynamics. 2016;4:19-30. (In Russ.)
  56. Podoprigora VG. Oxidative stress and peptic ulcer disease. M.: Medicine; 2004. (In Russ.)
  57. Mosesova NS. Study of the anti-inflammatory properties of Mexidol in acute and chronic inflammation: abstract dis. on competition of a scientific degree: Dis... cand. med. sciences. Kupavna; 2006. (In Russ.)
  58. Odintsova NF. Mexidol in complex therapy of arterial hypertension in patients of elderly and senile age. Farmateka. 2006;20:19-30. (In Russ.)
  59. Mayorova NG, Pavlova VA. Clinical experience of application of Neurox in patients with cerebrovascular disease. Neurology, neuropsychiatry, psychosomatics. 2011;1:71-74. (In Russ.)

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.